PostPoems Be Artistic. Be Creative. Be Inspired!

In May of 2003,
network news reported
many cases of heart
inflammation from the
newest version of
'smallpox vaccine'.

George W Merck of Merck Pharmaceuticals for several
decades developed biological weapons for the Dept of Defense. He is
listed as a DOD biological weapons contractor and testified before
Congress' science committee about his activities. These weapons were developed at West Point Pa (not NY). They include 'smallpox vaccine'
given to African countries, 'vaccine' which caused AIDS
throughout Africa. In addition, Merck headed the campaign
to target US gays with AIDS through 'hepatitis' vaccines. Merck used
Nazi research on the biological vulnerabilities of Africans and
gays. "Smallpox vaccine" was developed by slashing the stomachs of
calves, spraying them with live smallpox, and then several weeks
later planing off the scab and grinding it into powder. It created
bovine leukemia virus (* the same disease as human leukemia virus
except in a cow).
Recently the Red Cross has eliminated blood from those with insulin
derived from cows.
The London Times, President Mbeki of S Africa, Dr Robert Strecker of
California and others have reported
on the amazing correlation (a 17 point match in exact sequence)
between countries receiving WHO smallpox vaccine and the outbreak
of AIDS.
Merck is an underwriter on All Things Considered of NPR, whose board
was
taken over by the military during Desert Storm. What UN inspectors
are monitoring Merck, Glaxo Smith Kline, Ft Detrick Ft Meade
Battelle Smithsonian Dugway Proving Ground Univ of Texas Texas Tech
and other places biological weapons are stored?
atc@n...,wesat@n...,wesun@n...
http://www.mad-cow.org http://www.pcrm.org http://www.meatout.com
http://www.whatreallyhappened.com
http://www.poetsagainstthewar.org http://www.citiesforpeace.org

Glaxo Smith Kline is a developer of the current smallpox
vaccine.General Thomas
White, formerly with Enron, made 62 million dollars at that
corporation.

Coors Stadium selling fried bull testicles
http://www.postpoems.com/members/truths (see Coors)
Ward Egg Farm in San Diego sent 30,000 chickens through chipper
http://www.postpoems.com/members/truths

Bill Gates' Microsoft has been blocking from MSN the email
of those working against the primate abuse at Duke being funded
by Gates.

ONE HALF OF BRITISH SOLDIERS REFUSING ANTHRAX VACCINE
while Dr Slaughter of the Navy has said that half of the American
soldiers who must
take the vaccine or face court martial are showing serious side
effects.
Captain Joyce Riley of the USAF has testified before Congress that
20,000 to 40,000 American Gulf War vets have died of anthrax vaccine
complications.

Bush junta breaks 40 year tradition in calling first on Helen
Thomas, dean of the Washington press corps. Helen Thomas
takes a strong peace stand.

Marcy Kaptur was abused by Paul Begala, warmonger in Democrat clothing. While we boycott CNN, we urge all to contact the warmonger
network to have Begala replaced on Crossfire by a true populist.
feedback@cnn.com

http://n05.moneycentral.msn.com/ticker/article.asp?
Symbol=US:MRK&Feed=BW&Date=20020819&ID=1866960

The Law Firm of Berger & Montague, P.C. Announces Class Action
Lawsuit Against Merck
August 19, 2002 10:03:00 AM ET

PHILADELPHIA--(BUSINESS WIRE)--Aug. 19, 2002--On July 10, 2002, the
law firm of Berger & Montague, P.C. (http://www.bergermontague.com)
filed a class action suit against Merck & Co. Inc. ("Merck") MRK and
certain of its principal officers and directors in the United States
District Court for the District of New Jersey on behalf of all
persons or entities who purchased Merck common stock between July 23,
1999 and July 3, 2002 (the "Class Period").
The complaint alleges that defendants violated the federal securities
laws by issuing materially false and misleading statements throughout
the Class Period that had the effect of artificially inflating the
market price of Merck's common stock.
Merck's operations are comprised of two reportable segments: Merck
Pharmaceutical and Merck's wholly owned subsidiary, Merck-Medco
Managed Care, L.L.C. ("Merck-Medco"), which manages pharmacy benefits
for employers, insurers and other plan sponsors. Consumers who are
members of pharmacy benefits plans must make co-payments directly to
the pharmacy when purchasing prescriptions.
Since Merck acquired Merck-Medco in 1993 and throughout the Class
Period, Merck and Merck-Medco have falsely inflated their reported
revenues by billions of dollars, by approximately $14 billion from
1999-2002, by including consumer co-payments for prescription drugs
in revenue, contrary to the revenue recognition practices of two of
Merck-Medco's biggest competitors and concealing these facts in
violation of Generally Accepted Accounting Principles ("GAAP").
As a result, defendants concealed these facts, overstating Merck-
Medco's total economic activity, making it appear more successful
than it actually was.
On July 5, 2002, Merck filed with the SEC Amendment No. 4 to the Form
S-1 Registration Statement for the initial public offering ("IPO") of
shares of Medco Health Solutions, Inc., its former Merck-Medco unit.
In that document, defendants disclosed for the first time the
material amounts of the co-payments included in product net revenues,
as follows:
Retail copayments included in product net revenues amount
to approximately $2,838 million in 1999, $4,036 million in
2000, $5,537 million in 2001, $1,378 million in the first
quarter of 2001 and $1,640 million in the first quarter of
2002, each with a corresponding equivalent amount recorded in
cost of product net revenues.
Therefore, between 1999 and 2001, co-payments represented nearly 10%
of Merck's overall reported revenue. Medco's co-payments of $5.5
billion booked as revenue in 2001 represented approximately 11% of
Merck's 2001 overall revenue of $50.69 billion.
The co-payment revenue booked in 2000 was $4.04 billion, or
approximately 9.4% of Merck's total reported revenue, while it was
$2.84 billion in 1999, or approximately 8.1% of total revenue.
Following defendants' July 5, 2002 disclosure of approximately $14
billion of co-payments included in product net revenues from 1999-
2002, the price of Merck stock dropped approximately 14% to as low as
$45 and Merrill Lynch dropped its "buy" rating on Merck stock. The
Medco IPO has been delayed three times and Merck has reduced the
expected price range to $20-$22 from $22.-$24.
If you purchased Merck common stock during the period from July 23,
1999 through July 3, 2002, inclusive, you may, no later than August
20, 2002, move to be appointed as a Lead Plaintiff. A Lead Plaintiff
is a representative party that acts on behalf of other class members
in directing the litigation.
The Private Securities Litigation Reform Act of 1995 directs courts
to assume that the class member(s) with the "largest financial
interest" in the outcome of the case will best serve the class in
this capacity.
Courts have discretion in determining which class member(s) have
the "largest financial interest," and have appointed Lead Plaintiffs
with substantial losses in both absolute terms and as a percentage of
their net worth.
If you have sustained substantial losses in Merck common stock during
the Class Period, please contact Berger & Montague, P.C. at
investorprotect@b... for a more thorough explanation of the Lead
Plaintiff selection process.
The law firm of Berger & Montague, P.C. has over 50 attorneys, all of
whom represent plaintiffs in complex litigation. The Berger firm has
extensive experience representing plaintiffs in class action
securities litigation and has played lead roles in major cases over
the past 25 years which have resulted in recoveries of several
billion dollars to investors.
The firm has represented investors as lead counsel in actions against
companies including Rite Aid, Sotheby's, Waste Management, Inc.,
Sunbeam, Boston Chicken and IKON Office Solutions, Inc. The standing
of Berger & Montague, P.C. in successfully conducting major
securities and antitrust litigation has been recognized by numerous
courts. For example:
"Class counsel did a remarkable job in representing the
class interests." In Re: IKON Offices Solutions
Securities Litigation. Civil Action No. 98-4286(E.D.Pa.)
(partial settlement for $111 million approved May,
2000). "...(Y)ou have acted the way lawyers at their best
ought to act. And I have had a lot of cases...in 15 years
now as a judge and I cannot recall a significant case where
I felt people were better represented than they are
here ...I would say this has been the best representation
that I have seen." In Re: Waste Management, Inc. Securities
Litigation, Civil Action No. 97-C 7709 (N.D. Ill.) (settled
in 1999 for $220 million).
If you purchased Merck common stock during the Class Period, please
visit our website at www.bergermontague.com to view the complaint and
join the class action or if you have any questions concerning this
notice or your rights with respect to this matter, please contact:
Sherrie R. Savett, Esquire Carole A. Broderick,
Esquire Barbara A. Podell, Esquire Kimberly A.
Walker, Investor Relations Manager Berger & Montague,
P.C. 1622 Locust Street Philadelphia, PA
19103 Phone: 888-891-2289 or 215-875-3000 Fax: 215-
875-5715 Website: http://www.bergermontague.com e-
mail: InvestorProtect@b...
Contact Information:
Berger & Montague, P.C., Philadelphia
Sherrie R. Savett, Esquire
or
Carole A. Broderick, Esquire
or
Barbara A. Podell, Esquire
or
Kimberly A. Walker
888/891-2289 or 215/875-3000

� 2002 BusinessWire